Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer - Trial NCT06419673
Access comprehensive clinical trial information for NCT06419673 through Pure Global AI's free database. This Phase 2 trial is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences and is currently Recruitment Completed. The study focuses on Cervical Cancer. Target enrollment is 240 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Timeline & Enrollment
Phase 2
May 01, 2024
May 31, 2028
Primary Outcome
Progression-Free Survival(PFS) at Month 36
Summary
This study is a prospective, multicenter, randomized, open controlled clinical trial aimed at
 evaluating the effectiveness and safety of serplulimab plus chemoradiotherapy in FIGO 2018
 stage III or IVA cervical squamous cell carcinoma, adenocarcinoma, and adenosquamous cell
 carcinoma patients who have not received prior treatment.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06419673
Non-Device Trial